High-risk lesions in immunosuppression — Rapid

Synopsis

Recognise accelerated keratinocyte and virus-associated cancer risk during immune suppression, lower thresholds for urgent biopsy, coordinate surveillance and prevention, and modify systemic treatment only through multidisciplinary care.

Solid-organ transplant recipients have a markedly increased cutaneous SCC burden, with greater multiplicity, recurrence, nodal spread and disease-specific mortality.
Chronic lymphocytic leukaemia, lymphoma, HIV, stem-cell transplantation and long-term immunosuppressive medicines also change tumour behaviour and diagnostic thresholds.
Do not wait for a lesion to satisfy every standard size criterion; rapid growth, pain, keratin, ulceration or an outlier pattern warrants urgent biopsy.
Examine the whole skin, scalp, lips, ears, palms, soles, nails and genital region according to consent and risk, plus relevant nodal basins.
Provide regular specialist surveillance based on immune state and previous tumour burden, with rapid access between routine appointments.
Combine shade, clothing, broad-brimmed hats and broad-spectrum sunscreen; sunscreen complements rather than replaces physical protection.
Treat actinic field change and every suspicious invasive focus separately; field cream must not conceal a thick or tender SCC.
Never stop or reduce transplant, cancer or inflammatory-disease immunosuppression independently; balance graft or disease control with cancer risk in the multidisciplinary team.

Key red flags

Any rapidly growing, painful, indurated, ulcerated or bleeding lesion, lip or ear tumour, neurological symptom, regional node, widespread eruptive lesions or a changing transplant-associated scar requires urgent skin-cancer assessment.

Aggressive SCC phenotype

Rapidly enlarging painful indurated keratin, ulceration, lip or ear site and recurrence demand urgent assessment.

Perineural or nodal disease

Numbness, weakness, severe pain or a firm regional node indicates possible advanced SCC.

Investigation priorities

Baseline full-skin and node examinationFirst step

Establish tumour burden, field damage and sites needing biopsy or surveillance.

Management branches

Routine high-risk surveillanceBuild a rapid-access prevention system

A patient has ongoing immune suppression with no current invasive warning.

Record immune therapy and previous tumours, perform risk-based full-skin and node examination and set the next interval.
Teach practical self-examination and layered ultraviolet protection and provide direct instructions for lesions that cannot wait.
Treat field change and review HPV prevention, smoking and occupational exposure while keeping invasive outliers outside field protocols.

Key medicines

Acitretin capsulesUse only a specialist-selected individual dose for secondary chemoprevention, commonly starting low and titrating to tolerability under the current SmPC.Highly teratogenic with prolonged post-treatment pregnancy prevention, hepatotoxic and lipid-altering; review alcohol, interactions, mood, bone and mucocutaneous effects and never use without expert monitoring.

Open full textbook →Answer 2 questions